Breaks Categories: News

TuesdayJun 17, 2025 9:10 am

NetworkNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) CEO Highlights Fingerprint Drug Testing on BioMedWire Podcast

Intelligent Bio Solutions (NASDAQ: INBS) CEO Harry Simeonidis joined the latest episode of The BioMedWire Podcast to discuss the company’s rapid, non-invasive drug screening platform and global expansion strategy. Simeonidis detailed how the company’s fingerprint-based technology detects drug use through sweat, enabling faster and more affordable workplace screening. With current deployments in about 20 countries and an FDA application under review, Intelligent Bio Solutions is targeting U.S. market entry in the second half of 2025 and expects to scale through distributor partnerships and targeted marketing. To view the full article, visit https://nnw.fm/B3ENr About Intelligent Bio Solutions Inc. Intelligent Bio Solutions…

Continue Reading

TuesdayJun 17, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring

HeartBeam to integrate AccurECG(TM), AccurKardia’s FDA-cleared ECG analysis software Collaboration enhances HeartBeam’s commercial offering with automated arrhythmia insights Combined platform aims to improve cardiac care access and speed time to diagnosis HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with AccurKardia, a leader in automated ECG diagnostics, to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s cable-free, credit card-sized 3D ECG device. The partnership unites two innovators in ambulatory cardiac monitoring to create a more scalable, accessible solution for arrhythmia detection and management. HeartBeam’s device captures electrical signals in three non-coplanar directions and synthesizes them into a 12-lead ECG for remote use.…

Continue Reading

MondayJun 16, 2025 3:21 pm

NetworkNewsBreaks – ROTH’s 15th Annual London Conference to Showcase Market Trends, Compelling Investment Opportunities

Roth Capital Partners (“ROTH”), www.roth.com, today announced the agenda and details for its 15th Annual London Conference, which is slated to take place at the Four Seasons Hotel at Park Lane in London on June 24-26, 2025. The event is designed to foster meaningful dialogue between institutional investors and C-suite leaders and senior executives from approximately 80 companies with a strong focus on the sustainability and technology sectors. "We look forward to hosting the 15th edition of our flagship London conference," said ROTH’s Executive Chairman Byron Roth. "This event creates a unique environment for our corporate clients to engage directly…

Continue Reading

MondayJun 16, 2025 10:20 am

NetworkNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieving a durable complete response following treatment with LP-300 in combination with standard chemotherapy. The patient, who had previously failed three lines of therapy including Keytruda(R), radiation, and Tagrisso(R), initially saw a 57% tumor reduction and later achieved full resolution of lung and adrenal lesions. Nearly two years after treatment initiation, the patient remains progression-free and has experienced no clinically significant adverse reactions across 21 cycles. This sustained response underscores the potential of LP-300, developed…

Continue Reading

MondayJun 16, 2025 9:48 am

NetworkNewsBreaks – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Advances 2.4 MW Community Solar Project in Nova Scotia 

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) announced progress on its 2.4 MW DC Sydney project in Nova Scotia, reinforcing its expansion in the Canadian community solar market. Valued at $4.57 million and developed in partnership with AI Renewable Flow-through Fund and Trimac Engineering, the project is expected to produce 2,730 MWh of clean energy annually—enough to power 221 homes and offset 1,900 tons of CO₂. Construction is slated for spring 2026, with SolarBank serving as developer and EPC contractor. The company anticipates near-term engineering revenues and long-term income from operations and maintenance contracts while supporting Nova Scotia’s goal…

Continue Reading

MondayJun 16, 2025 9:20 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm specializing in life sciences. The collaboration comes as NRx advances toward two NDA filings, an ANDA submission, and expands its interventional psychiatry clinic acquisitions. Led by veterans of The Trout Group, astr will support NRx and HOPE with investor targeting, message development, earnings prep, and institutional outreach to enhance visibility and engagement. To view the full press release, visit https://nnw.fm/hL3y3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on…

Continue Reading

MondayJun 16, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam’s credit card-sized device demonstrated 93.4% diagnostic agreement with standard ECGs VALID-ECG study results presented at Heart Rhythm Society conference Company eyes U.S. commercialization pending FDA clearance HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society’s annual meeting in San Diego, validate HeartBeam’s compact, patient-friendly ECG technology. The study compared ECG intervals and amplitudes between HeartBeam’s synthesized output and simultaneously collected standard ECGs in 198 patients across…

Continue Reading

FridayJun 13, 2025 2:51 pm

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reported Q1 2025 Results, Advanced Toward Commercialization Following VALID-ECG Study Success

HeartBeam (NASDAQ: BEAT) reported financial results and operational highlights for the first quarter of 2025, marking significant progress toward commercialization of its 12-lead ECG synthesis software. The company successfully met clinical endpoints in its VALID-ECG pivotal study, demonstrating a 93.4% diagnostic agreement with standard ECGs, and engaged in productive discussions with the FDA on its 510(k) submission. During the quarter, HeartBeam entered a strategic collaboration with AccurKardia to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s compact, cable-free cardiac device. The partnership was expected to accelerate product development and improve access to rapid arrhythmia diagnosis. The company also expanded its intellectual…

Continue Reading

FridayJun 13, 2025 10:55 am

NetworkNewsBreaks – RedCloud Holdings plc (NASDAQ: RCT) to Participate in ROTH 15th Annual London Conference

RedCloud Holdings (NASDAQ: RCT) announced that CEO and Co-Founder Justin Floyd will attend the ROTH 15th Annual London Conference, taking place at the Four Seasons Hotel London at Park Lane. The event provides a platform for RedCloud to engage with investors and industry stakeholders in an international setting. To view the full press release, visit https://nnw.fm/b0bdT About RedCloud RedCloud has developed and operates the RedCloud trading platform (the “Platform”), that facilities trade of everyday consumer supplies of fast-moving consumer goods (“FMCG”) products across business supply chains. RedCloud believes its Platform solves a decades old problem of how to unlock and…

Continue Reading

ThursdayJun 12, 2025 10:35 am

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights Growth and SEPA Funding Ahead of BIO 2025 CEO Participation

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that CEO Amir Reichman will participate in the BIO International Convention 2025, taking place June 16–19 in Boston. The company will present recent strategic, operational, and financial milestones, including its rapid CDMO business growth and progress on its nanobody pipeline. Scinai recently secured $1.38 million in funding via its Standby Equity Purchase Agreement with Yorkville Advisors, boosting capital without warrants or additional dilution. The company reaffirmed 2025 CDMO revenue guidance of $2 million and targets breakeven in 2026. To view the full press release, visit https://nnw.fm/0j1hv About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company…

Continue Reading